This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to
determine the safety, tolerability, efficacy, PK of bb2121 in combination with other
therapies in adult subjects with R/RMM.
The following combinations will be
Arm A will test bb2121 in combination with CC-220 ( low-dose dexamethasone)
Arm B will test bb2121 in combination with BMS-986405 (JSMD194)
Arm C will test bb2121 in combination with one of the following standard triplet
regimens: 1) Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose
dexamethasone (DPd); 2) Pomalidomide (POM) in combination with bortezomib (BTZ) and
low-dose dexamethasone (PVd)
Combination agents being tested may be administered before, concurrently with and/or
following (ie, maintenance) bb2121 infusion.
The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose
expansion may occur in one or more arms.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.